Advertisement

Immunologic Research

, Volume 57, Issue 1–3, pp 34–43 | Cite as

New therapeutic approaches for protecting hematopoietic stem cells in aplastic anemia

  • Wendy Weston
  • Vineet Gupta
  • Rebecca Adkins
  • Roland Jurecic
Immunology & Microbiology in Miami

Abstract

Aplastic anemia (AA) is an immune-mediated and life-threatening form of acquired bone marrow failure (BMF), characterized by development and expansion of self-reactive T cells. These T cells cause continuous destruction of hematopoietic stem cells (HSCs), progenitors, and mature blood cells, leading to severe and if left untreated fatal marrow hypoplasia and pancytopenia. Standard treatment options for patients with AA include: (1) immunosuppressive therapy (IST) with anti-thymocyte globulin and cyclosporine A which targets self-reactive T cells, or (2) matched sibling or unrelated BM transplant (BMT). The IST treatment is often not effective due to poor response to therapy or disease relapse after IST. Also, BMT is not an option for many patients due to their age, comorbidities, and the lack of histocompatible donor. This necessitates development and testing of novel approaches to reduce severity of AA and to efficiently treat patients with refractory and relapsed AA. Immune-mediated AA was reproduced in animals, including mouse lymphocyte infusion models, which are used to study further etiology and pathophysiology of AA and test new drugs and approaches in treating and managing AA. In these mouse models the immune correlates and pathologic features of AA are strikingly similar to features of severe human AA. In this article we (a) briefly review standard and developing approaches for treating AA and (b) describe development and testing of novel treatment approach with a potential to safely reduce BM hypoplasia and significantly decrease the loss of HSCs in mouse lymphocyte infusion model of AA.

Keywords

Aplastic anemia Bone marrow failure Hematopoietic stem cells T cells Dendritic cells β2 integrin CD11b/CD18 Immunosuppressive therapy 

Notes

Acknowledgments

This work is supported by UMMSM Interdisciplinary Team Science Pilot Program Grant (to R.J.).

Conflict of interest

W.W., R.A., and R.J. have no conflict of interest. V.G. is an inventor of pending patents related to Leukadherins and has the potential for financial benefit from their future commercialization.

References

  1. 1.
    Young NS, editor. Bone marrow failure syndromes. Philadelphia: WB Saunders; 2000.Google Scholar
  2. 2.
    Li JP, Zheng CL, Han ZC. Abnormal immunity and stem/progenitor cells in acquired aplastic anemia. Crit Rev Oncol Hematol. 2010;75:79–93.CrossRefPubMedGoogle Scholar
  3. 3.
    Young NS, Scheinberg P, Calado RT. Aplastic anemia. Curr Opin Hematol. 2008;15:162–8.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Young NS, Kaufman DW. The epidemiology of acquired aplastic anemia. Haematologica. 2008;93:489–92.CrossRefPubMedGoogle Scholar
  5. 5.
    Risitano AM, Maciejewski JP, Green S, Plasilova M, Zeng W, Young NS. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet. 2004;364:355–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2509–19.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Segel GB, Lichtman MA (2010). Aplastic anemia: acquired and Inherited, Chapter 34. In Williams Hematology, Eighth Edition. McGraw-Hill 2010.Google Scholar
  8. 8.
    Fliedner TM, et al. Structure and function of bone marrow hemopoiesis: mechanisms of response to ionizing radiation exposure. Cancer Biother Radiopharm. 2002;17:405–26.CrossRefPubMedGoogle Scholar
  9. 9.
    Meng A, Wang Y, Van Zant G, Zhou D. Ionizing radiation and busulfan induce premature senescence in murine bone marrow hematopoietic cells. Cancer Res. 2003;63:5414–9.PubMedGoogle Scholar
  10. 10.
    Meng A, Wang Y, Brown SA, Van Zant G, Zhou D. Ionizing radiation and busulfan inhibit murine bone marrow cell hematopoietic function via apoptosis-dependent and -independent mechanisms. Exp Hematol. 2003;31:1348–56.CrossRefPubMedGoogle Scholar
  11. 11.
    Bagby GC, Meyers G. Myelodysplasia and acute leukemia as late complications of marrow failure: future prospects for leukemia prevention. Hematol Oncol Clin North Am. 2009;23:361–76.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Bagby GC, Meyers G. Bone marrow failure syndromes. Preface. Hematol Oncol Clin North Am. 2009;23:8–14.Google Scholar
  13. 13.
    Myers KC, Davies SM. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant. 2009;15:279–92.CrossRefPubMedGoogle Scholar
  14. 14.
    Peinemann F, Grouven U, Kröger N, Pittler M, Zschorlich B, Lange S. Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review. Haematologica. 2009;94:1732–42.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Risitano AM. Immunosuppressive therapies in the management of acquired immune-mediated marrow failures. Curr Opin Hematol. 2012;19:3–13.CrossRefPubMedGoogle Scholar
  16. 16.
    Marsh JC, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147:43–70.CrossRefPubMedGoogle Scholar
  17. 17.
    Young NS, Bacigalupo A, Marsh JC. Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S119–25.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Afable MG 2nd, Tiu RV, Maciejewski JP. Clonal evolution in aplastic anemia. Hematol Am Soc Hematol Educ Program. 2011;2011:90–5.CrossRefGoogle Scholar
  19. 19.
    Afable MG 2nd, et al. SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood. 2011;117:6876–84.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Risitano AM, et al. Working Party Severe Aplastic Anaemia (WPSAA) of the European Group for Blood and Marrow Transplantation (EBMT). Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol. 2010;148:791–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Piccin A, et al. Aplastic Anaemia Working Party of the European Group for Blood and Marrow Transplantation. Survival of patients with documented autologous recovery after SCT for severe aplastic anemia: a study by the WPSAA of the EBMT. Bone Marrow Transplant. 2010;45:1008–13.CrossRefPubMedGoogle Scholar
  22. 22.
    Bacigalupo A, et al. Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. Haematologica. 2010;95:976–82.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Marsh J, et al. European Group for Blood and Marrow Transplantation (EBMT) Severe Aplastic Anaemia Working Party. Should irradiated blood products be given routinely to all patients with aplastic anaemia undergoing immunosuppressive therapy with antithymocyte globulin (ATG)? A survey from the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Br J Haematol. 2010;150:377–9.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Afable MG 2nd, et al. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica. 2011;96:1269–75.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Pulsipher MA, et al. Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant. 2011;17:291–9.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Olnes MJ, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367:11–9.PubMedCentralCrossRefPubMedGoogle Scholar
  27. 27.
    Barnes DWH, Mole RH. Aplastic anaemia in sublethally irradiated mice given allogeneic lymph node cells. Br J Haematol. 1967;13:482–91.CrossRefPubMedGoogle Scholar
  28. 28.
    Morley A, Blake J. An animal model of chronic aplastic marrow failure, I: late marrow failure after busulfan. Blood. 1974;4:49–56.Google Scholar
  29. 29.
    Knospe WH, Steinberg D, Speck B. Experimental immunologically mediated aplastic anemia (AA) in H-2 k identical, mLs (M) locus different mice. Exp Hematol. 1983;11:542–52.PubMedGoogle Scholar
  30. 30.
    Knospe WH, Steinberg D, Gratwohl A, Speck B. Experimental immunologically mediated aplastic anemia (AA) in mice: cyclosporin A fails to protect against AA. Int J Cell Cloning. 1984;2:263–71.CrossRefPubMedGoogle Scholar
  31. 31.
    Chiu KM, Knospe WH. Immunologically mediated aplastic anemia in mice: effects of varying the source and composition of donor cells. Exp Hematol. 1987;15:269–75.PubMedGoogle Scholar
  32. 32.
    Hayashi NM, Abe F, Takita T, Nakamura T, Takeuchi T, Umezawa H. Therapy of experimental immunologically mediated aplastic anemia in mice by various immunosuppressive and antitumor agents. Transplant Proc. 1988;20:545–8.PubMedGoogle Scholar
  33. 33.
    Knospe WH, Husseini SG, Chiu KM, Fried W. Immunologically mediated aplastic anemia in mice: evidence of hematopoietic stromal injury and injury to hematopoietic stem cells. Exp Hematol. 1994;22:573–81.PubMedGoogle Scholar
  34. 34.
    Bloom ML, et al. A mouse model of lymphocyte infusion-induced bone marrow failure. Exp Hematol. 2004;32:1163–72.CrossRefPubMedGoogle Scholar
  35. 35.
    Chen J. Animal models for acquired bone marrow failure syndromes. Clin Med Res. 2005;3:102–8.PubMedCentralCrossRefPubMedGoogle Scholar
  36. 36.
    Risitano AM. New challenges to developing animal models for human immune-mediated marrow failure. Clin Med Res. 2005;3:63–4.PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Broomhall KS, Morin M, Pevear DC, Pfau CJ. Severe and transient pancytopenia associated with a chronic arenavirus infection. J Exp Pathol. 1987;3:259–69.PubMedGoogle Scholar
  38. 38.
    Stellrecht-Broomhall KA. Evidence for immune-mediated destruction as mechanism for LCMV-induced anemia in persistently infected mice. Viral Immunol. 1991;4:269–820.CrossRefPubMedGoogle Scholar
  39. 39.
    Mayer A, Podlech J, Kurz S, Steffens HP, Maiberger S, Thalmeier K, Angele P, Dreher L, Reddehase MJ. Bone marrow failure by cytomegalovirus is associated with an in vivo deficiency in the expression of essential stromal hemopoietin genes. J Virol. 1997;71:4589–98.PubMedCentralPubMedGoogle Scholar
  40. 40.
    Binder D, van den Broek MF, Kägi D, Bluethmann H, Fehr J, Hengartner H, Zinkernagel RM. Aplastic anemia rescued by exhaustion of cytokine-secreting CD8+T cells in persistent infection with lymphocytic choriomeningitis virus. J Exp Med. 1998;187:1903–20.PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Binder D, Fehr J, Hengartner H, Zinkernagel RM. Virus-induced transient bone marrow aplasia: major role of interferon-alpha/beta during acute infection with the noncytopathic lymphocytic choriomeningitis virus. J Exp Med. 1997;185:517–30.PubMedCentralCrossRefPubMedGoogle Scholar
  42. 42.
    Chen J, et al. Bystander destruction of hematopoietic progenitor and stem cells in a mouse model of infusion-induced bone marrow failure. Blood. 2004;104:1671–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Turton JA, et al. Further development of a model of chronic bone marrow aplasia in the busulphan-treated mouse. Int J Exp Pathol. 2006;87(4):9–63.Google Scholar
  44. 44.
    Chen J, Ellison FM, Eckhaus MA, Smith AL, Keyvanfar K, Calado RT, Young NS. Minor antigen h60-mediated aplastic anemia is ameliorated by immunosuppression and the infusion of regulatory T cells. J. Immunol. 2007;178:4159–68.CrossRefPubMedGoogle Scholar
  45. 45.
    Sarcon AK, Desierto MJ, Zhou W, Visconte V, Gibellini F, Chen J, Young NS. Role of perforin-mediated cell apoptosis in murine models of infusion-induced bone marrow failure. Exp Hematol. 2009;37:477–86.PubMedCentralCrossRefPubMedGoogle Scholar
  46. 46.
    Tang Y, Desierto MJ, Chen J, Young NS. The role of the Th1 transcription factor T-bet in a mouse model of immune-mediated bone-marrow failure. Blood. 2010;115:541–8.PubMedCentralCrossRefPubMedGoogle Scholar
  47. 47.
    de Latour RP, et al. Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood. 2010;116:4175–84.PubMedCentralCrossRefPubMedGoogle Scholar
  48. 48.
    Qiao X, Xie X, Jiang S, Shi W, Tang J, Zhou N. Experimental bone marrow failure in mice ameliorated by OCH via tippling the balance of released cytokines from Th1 to Th2. Immunopharmacol Immunotoxicol. 2012;34:491–8.CrossRefPubMedGoogle Scholar
  49. 49.
    Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 1995;85:3183–90.PubMedGoogle Scholar
  50. 50.
    Erie AJ, et al. MHC class II upregulation and colocalization with Fas in experimental models of immune-mediated bone marrow failure. Exp Hematol. 2011;39:837–49.PubMedCentralCrossRefPubMedGoogle Scholar
  51. 51.
    Roderick JE, et al. Therapeutic targeting of NOTCH signaling ameliorates immune-mediated bone marrow failure of aplastic anemia. J Exp Med. 2013;210:1311–29.PubMedCentralCrossRefPubMedGoogle Scholar
  52. 52.
    Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673–87.CrossRefPubMedGoogle Scholar
  53. 53.
    Mayadas TN, Cullere X. Neutrophil beta2 integrins: moderators of life or death decisions. Trends Immunol. 2005;26:388–95.CrossRefPubMedGoogle Scholar
  54. 54.
    Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7:678–89.CrossRefPubMedGoogle Scholar
  55. 55.
    Zhang Y, Wang H. Integrin signalling and function in immune cells. Immunology. 2012;135:268–75.PubMedCentralCrossRefPubMedGoogle Scholar
  56. 56.
    Kubota Y, Takubo K, Shimizu T, Ohno H, Kishi K, Shibuya M, et al. M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J Exp Med. 2009;206:1089–102.PubMedCentralCrossRefPubMedGoogle Scholar
  57. 57.
    Arnaout MA. Leukocyte adhesion molecules deficiency: its structural basis, pathophysiology and implications for modulating the inflammatory response. Immunol Rev. 1990;114:145–80.CrossRefPubMedGoogle Scholar
  58. 58.
    Phillipson M, Heit B, Colarusso P, Liu L, Ballantyne CM, Kubes P. Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. J Exp Med. 2006;203:2569–75.PubMedCentralCrossRefPubMedGoogle Scholar
  59. 59.
    Varga G, et al. Active MAC-1 (CD11b/CD18) on DCs inhibits full T-cell activation. Blood. 2007;109:661–9.CrossRefPubMedGoogle Scholar
  60. 60.
    Bai Y, Qian C, Qian L, Ma F, Hou J, Chen Y, Wang Q, Cao X. Integrin CD11b negatively regulates TLR9-triggered dendritic cell cross-priming by upregulating microRNA-146a. J Immunol. 2012;188:5293–302.CrossRefPubMedGoogle Scholar
  61. 61.
    Plow EF, Zhang LA. MAC-1 attack: integrin functions directly challenged in knockout mice. J Clin Invest. 1997;99:1145–6.PubMedCentralCrossRefPubMedGoogle Scholar
  62. 62.
    Jaeschke H, Farhood A, Bautista AP, Spolarics Z, Spitzer JJ, Smith CW. Functional inactivation of neutrophils with a Mac-1 (CD11b/CD18) monoclonal antibody protects against ischemia-reperfusion injury in rat liver. Hepatology. 1993;17:915–23.CrossRefPubMedGoogle Scholar
  63. 63.
    Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci USA. 1998;95:10134–9.PubMedCentralCrossRefPubMedGoogle Scholar
  64. 64.
    Wilson I, Gillinov AM, Curtis WE, DiNatale J, Burch RM, Gardner TJ, et al. Inhibition of neutrophil adherence improves postischemic ventricular performance of the neonatal heart. Circulation. 1993;88(5 Pt 2):II372–9.PubMedGoogle Scholar
  65. 65.
    Yonekawa K, Harlan JM. Targeting leukocyte integrins in human diseases. J Leukoc Biol. 2005;77:129–40.CrossRefPubMedGoogle Scholar
  66. 66.
    Dove A. CD18 trials disappoint again. Nat Biotechnol. 2000;18:817–8.CrossRefPubMedGoogle Scholar
  67. 67.
    Allison M. PML problems loom for Rituxan. Nat Biotechnol. 2010;28:105–6.CrossRefPubMedGoogle Scholar
  68. 68.
    Lum AF, Green CE, Lee GR, Staunton DE, Simon SI. Dynamic regulation of LFA-1 activation and neutrophil arrest on intercellular adhesion molecule 1 (ICAM-1) in shear flow. J Biol Chem. 2002;277:20660–70.CrossRefPubMedGoogle Scholar
  69. 69.
    Ramamoorthy C, Sasaki SS, Su DL, Sharar SR, Harlan JM, Winn RK. CD18 adhesion blockade decreases bacterial clearance and neutrophil recruitment after intrapulmonary E. coli, but not after S. aureus. J Leukoc Biol. 1997;61:167–72.PubMedGoogle Scholar
  70. 70.
    Gupta V. (2009). HTS identification of compounds that enhance the binding of CD11b/CD18 to fibrinogen via a luminescence assay. Pubchem Assay ID 1499.Google Scholar
  71. 71.
    Faridi MH, Maiguel D, Barth CJ, Stoub D, Day R, Schürer S, Gupta V. Identification of novel agonists of the integrin CD11b/CD18. Bioorg Med Chem Lett. 2009;19:6902–6.PubMedCentralCrossRefPubMedGoogle Scholar
  72. 72.
    Maiguel D, Faridi MH, Wei C, Kuwano Y, Balla KM, Hernandez D, Barth CJ, Lugo G, Donnelly M, Nayer A, Moita LF, Schürer S, Traver D, Ruiz P, Vazquez-Padron RI, Ley K, Reiser J, Gupta V. Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease. Sci Signal. 2011;4(189):ra57.PubMedCentralCrossRefPubMedGoogle Scholar
  73. 73.
    Bordon Y. Immunotherapy: Leukadherins get a grip on inflammation. Nat Rev Immunol. 2011;11:638.CrossRefPubMedGoogle Scholar
  74. 74.
    Faridi MH, Altintas MM, Gomez C, Duque JC, Vazquez-Padron RI, Gupta V. Small molecule agonists of integrin CD11b/CD18 do not induce global conformational changes and are significantly better than activating antibodies in reducing vascular injury. Biochim Biophys Acta. 2013;1830:3696–710.PubMedCentralCrossRefPubMedGoogle Scholar
  75. 75.
    Tourkova IL, Yurkovetsky ZR, Shurin MR, Shurin GV. Mechanisms of dendritic cell-induced T cell proliferation in the primary MLR assay. Immunol Lett. 2001;78:75–82.CrossRefPubMedGoogle Scholar
  76. 76.
    Rose S, Guevara P, Farach S, Adkins B. The key regulators of adult T helper cell responses, STAT6 and T-bet, are established in early life in mice. Eur J Immunol. 2006;36:1241–53.PubMedCentralCrossRefPubMedGoogle Scholar
  77. 77.
    Rose S, Lichtenheld M, Foote M, Adkins B. Murine neonatal CD4 + cells are poised for rapid Th2 effector-like function. J Immunol. 2007;178:2667–78.PubMedCentralCrossRefPubMedGoogle Scholar
  78. 78.
    Jurecic R, Van NT, Belmont JW. Enrichment and functional characterization of Sca-1+WGA+, LinWGA+, LinSca-1+ and LinSca-1+WGA+ bone marrow cells from mice with a Ly-6a haplotype. Blood. 1993;82:2673–83.PubMedGoogle Scholar
  79. 79.
    Morrison SJ, Weissman IL. The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype. Immunity. 1994;1:661–73.CrossRefPubMedGoogle Scholar
  80. 80.
    Li CL, Johnson GR. Murine hematopoietic stem and progenitor cells: I. Enrichment and biologic characterization. Blood. 1995;85:1472–9.PubMedGoogle Scholar
  81. 81.
    Christensen JL, Weissman IL. Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. PNAS. 2001;98:14541–6.PubMedCentralCrossRefPubMedGoogle Scholar
  82. 82.
    Adolfsson J, Borge OJ, Bryder D, Theilgaard-Monch K, Astrand-Grundstrom I, Sitnicka E, Sasaki Y, Jacobsen SE. Upregulation of Flt3 expression within the bone marrow Lin(-)Sca1(+)c-kit(+) stem cell compartment is accompanied by loss of self-renewal capacity. Immunity. 2001;15:659–69.CrossRefPubMedGoogle Scholar
  83. 83.
    Yang L, Bryder D, Adolfsson J, Nygren J, Månsson R, Sigvardsson M, Jacobsen SE. Identification of Lin(-)Sca1(+)kit(+)CD34(+)Flt3- short-term hematopoietic stem cells capable of rapidly reconstituting and rescuing myeloablated transplant recipients. Blood. 2005;105:2717–23.CrossRefPubMedGoogle Scholar
  84. 84.
    Adolfsson J, Mansson R, Buza-Vidas N, Hultquist A, Liuba K, Jensen CT, Bryder D, Yang L, Borge OJ, Thoren LA, et al. Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic potential a revised road map for adult blood lineage commitment. Cell. 2005;121:295–306.CrossRefPubMedGoogle Scholar
  85. 85.
    Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell. 2005;121(7):1109–21.CrossRefPubMedGoogle Scholar
  86. 86.
    Zayas J, Spassov DS, Nachtman RG, Jurecic R. Murine hematopoietic stem cells and multipotent progenitors express truncated intracellular form of c-kit receptor. Stem Cells Dev. 2008;17:343–53.PubMedCentralCrossRefPubMedGoogle Scholar
  87. 87.
    Kiel MJ, Yilmaz OH, Morrison SJ. CD150- cells are transiently reconstituting multipotent progenitors with little or no stem cell activity. Blood. 2008;111(8):4413–4.PubMedCentralCrossRefPubMedGoogle Scholar
  88. 88.
    Morita Y, Ema H, Nakauchi H. Heterogeneity and hierarchy within the most primitive hematopoietic stem cell compartment. J Exp Med. 2010;207:1173–82.PubMedCentralCrossRefPubMedGoogle Scholar
  89. 89.
    Simon G, et al. Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. Diabetes. 2008;57:405–14.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Wendy Weston
    • 1
  • Vineet Gupta
    • 2
  • Rebecca Adkins
    • 1
  • Roland Jurecic
    • 1
  1. 1.Department of Microbiology and Immunology, Miller School of MedicineUniversity of MiamiMiamiUSA
  2. 2.Department of MedicineRush University Medical CenterChicagoUSA

Personalised recommendations